OncoMatch/Clinical Trials/NCT06817525
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
Is NCT06817525 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1) and 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1) for triple-negative breast cancer.
Treatment: 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1) · 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1) — We plan to explore the efficacy and safety of albumin-bound paclitaxel+carboplatin+Camrelizumab in neoadjuvant therapy for early TNBC patients, optimize the administration method and drug combination therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) negative (ihc 0, 1+ without fish, or ihc 2+ without fish amplification)
Required: ESR1 negative (ihc nuclear staining <10%)
Required: PR (PGR) negative (ihc nuclear staining <10%)
Disease stage
Required: Stage CT4B, CT4C, CT4D, CT1C WITH AXILLARY LYMPH NODE METASTASIS (TNM)
Excluded: Stage IV
cT2- cT4d, or cT1c with axillary lymph node metastasis; There is evidence of metastatic breast cancer [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Have Received chemotherapy ... for this disease
Cannot have received: endocrine therapy
Have Received ... endocrine therapy ... for this disease
Cannot have received: targeted therapy
Have Received ... targeted therapy ... for this disease
Cannot have received: radiation therapy
Have Received ... radiation therapy ... for this disease
Cannot have received: anti-PD-1 therapy
Received treatment with anti-PD-1, anti-PDL1, anti-PD-L2 drugs, or other immunotherapy
Cannot have received: anti-PD-L1 therapy
Received treatment with anti-PD-1, anti-PDL1, anti-PD-L2 drugs, or other immunotherapy
Cannot have received: anti-PD-L2 therapy
Received treatment with anti-PD-1, anti-PDL1, anti-PD-L2 drugs, or other immunotherapy
Cannot have received: checkpoint inhibitor
Received treatment with anti-PD-1, anti-PDL1, anti-PD-L2 drugs, or other immunotherapy
Lab requirements
Blood counts
absolute value of neutrophil count ≥ 2.0 × 10^9/l; hemoglobin ≥ 100g/l; platelet count ≥ 100 × 10^9/l
Kidney function
creatinine <1.5 × uln
Liver function
total bilirubin <1.5 uln; ast/alt < 1.5×uln
Cardiac function
cardiac ultrasound ef value ≥ 55%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06817525 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 negative is a required biomarker for enrollment.
Does this trial require ESR1?
Yes, ESR1 negative is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR negative is a required biomarker for enrollment.
What disease stage is eligible?
Stage CT4B or CT4C or CT4D or CT1C WITH AXILLARY LYMPH NODE METASTASIS is required.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify